Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab
出版年份 2019 全文链接
标题
Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab
作者
关键词
-
出版物
Journal of Clinical Medicine
Volume 8, Issue 7, Pages 1011
出版商
MDPI AG
发表日期
2019-07-10
DOI
10.3390/jcm8071011
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients
- (2019) M. G. Dal Bello et al. Journal of Translational Medicine
- Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
- (2018) Sarah B. Goldberg et al. CLINICAL CANCER RESEARCH
- Circulating tumor cells count as a predictor of survival in lung cancer
- (2018) Konstantinos Syrigos et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity
- (2018) Sabrina Rossi et al. Immunotherapy
- Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study
- (2018) Scott Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
- (2018) Hira Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- IASLC Statement Paper: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC)
- (2018) Christian Rolfo et al. Journal of Thoracic Oncology
- PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab
- (2018) Nicolas Guibert et al. LUNG CANCER
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Emerging biomarkers for immune checkpoint inhibition in lung cancer
- (2018) George Cyriac et al. SEMINARS IN CANCER BIOLOGY
- The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring
- (2018) Jillian Wilhelmina Paulina Bracht et al. Current Oncology Reports
- Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer
- (2018) Etienne Giroux Leprieur et al. OncoImmunology
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
- (2018) Julie R. Brahmer et al. Journal for ImmunoTherapy of Cancer
- 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer
- (2018) Hossein Borghaei et al. Journal of Thoracic Oncology
- The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer
- (2018) Joanna Kapeleris et al. Frontiers in Oncology
- Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer
- (2018) Arsela Prelaj et al. EUROPEAN JOURNAL OF CANCER
- Very early response of circulating tumour–derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non–small cell lung cancer
- (2017) Yuki Iijima et al. EUROPEAN JOURNAL OF CANCER
- Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy
- (2017) Simona Coco et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
- (2017) Leora Horn et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non–Small Cell Lung Cancer:18F-FDG PET/CT Study
- (2017) Silvia Morbelli et al. JOURNAL OF NUCLEAR MEDICINE
- Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis
- (2017) Sarah Cargnin et al. Journal of Thoracic Oncology
- Prognostic significance of circulating tumor cells in non-small cell lung cancer patients undergoing chemotherapy
- (2017) Bing Tong et al. Oncotarget
- A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial
- (2016) M. Yanagita et al. CLINICAL CANCER RESEARCH
- Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
- (2016) Naiyer A. Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- The efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials
- (2016) Jiaxing Huang et al. OncoTargets and Therapy
- Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy
- (2016) C. Alix-Panabieres et al. Cancer Discovery
- Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer
- (2016) Bo Ai et al. Oncotarget
- Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab
- (2016) Chiara Nicolazzo et al. Scientific Reports
- Circulating free DNA concentration is an independent prognostic biomarker in lung cancer
- (2015) Claire Tissot et al. EUROPEAN RESPIRATORY JOURNAL
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2015) Scott N. Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Relationship between circulating tumour cell count and prognosis following chemotherapy in patients with advanced non-small-cell lung cancer
- (2015) Zixuan Zhang et al. RESPIROLOGY
- Prognostic and predictive relevance of circulating tumor cells in patients with non-small-cell lung cancer
- (2014) Angela Alama et al. DRUG DISCOVERY TODAY
- Evaluation of Circulating Tumor Cells and Related Events as Prognostic Factors and Surrogate Biomarkers in Advanced NSCLC Patients Receiving First-Line Systemic Treatment
- (2014) Laura Muinelo-Romay et al. Cancers
- Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non-Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib
- (2012) E. A. Punnoose et al. CLINICAL CANCER RESEARCH
- Relationship of Circulating Tumor Cells to the Effectiveness of Cytotoxic Chemotherapy in Patients With Metastatic Non-Small-Cell Lung Cancer
- (2012) Takashi Hirose et al. ONCOLOGY RESEARCH
- Plasma DNA Quantification in Lung Cancer Computed Tomography Screening
- (2008) Gabriella Sozzi et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search